{
    "nct_id": "NCT04669067",
    "official_title": "An Open-Label, Multicenter, Phase 1b/2 Study of the Safety and Efficacy of TL-895 Combined With KRT-232 in Patients With Relapsed/Refractory (R/R) FLT3+ Acute Myeloid Leukemia (AML)",
    "inclusion_criteria": "* TP53 wildtype AML\n* Relapsed/Refractory to at least one prior therapy, one of which must have included a FLT-3 inhibitor\n* FLT3 mutation (FLT3-TKD or FLT3-ITD)\n* ECOG 0-2\n* Adequate hematologic, hepatic, and renal functions\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* AML subtype 3\n* Prior treatment with MDM2 antagonist therapies\n* Eligible for HSCT",
    "miscellaneous_criteria": ""
}